Get started
Outlook Therapeutics, Inc.Outlook Therapeutics, Inc.Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

OTLK trade ideas

OTLK Long Trade Setup | Entry, SL, T1, T2!Type: Long Trade 📈 Entry Point: $2.31 (marked breakout level) Stop Loss (SL): $2.18 (marked in red) 🚫 Target 1 (T1): $2.44 (marked in yellow) 🟡 Target 2 (T2): $2.60 (marked in green) ✅ Reason for Long: Symmetrical triangle breakout pattern with bullish momentum. The price broke through the resistance at $2.31, indicating further upside potential. Confirmation: Strong breakout above resistance with a clear retest and hold near the breakout zone, supported by volume. Timeframe: 30-minute chart. @RIckAshby
NASDAQ:OTLKLong
by ProfittoPath
Outlook Therapeutics $2.24. Huge potential upside.Outlook Therapeutics are a bio drug company specialising in treating a progressive eyesight problem that affects millions of elderly people worldwide. The disease is called wet macular degeneration. Outlook have been given approval in Europe and the uk for their new treatment and plan to sell the treatment in these markets in the first half of 2025. Outlook’s application for FDA approval was postponed last December, they were asked to provide more information, the company says they are continuing the trial and plan to resubmit in the first quarter for FDA approval. If Outlook get approval, one post on the wires suggests that this is likely, the price will fly. There is only one other treatment currently available for this disease that affects 20 Million people in the USA.
NASDAQ:OTLKLong
by RIckAshby
OTLK Surged 22% On Positive Opinion from CHMPOutlook Therapeutics, Inc. (Nasdaq: NASDAQ:OTLK ), a pioneering biopharmaceutical company, has achieved a significant milestone in the realm of ophthalmic healthcare. With the recent issuance of a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), Outlook Therapeutics ( NASDAQ:OTLK ) inches closer to securing authorization for ONS-5010/LYTENAVA™, an investigational ophthalmic formulation of bevacizumab, as a treatment for wet age-related macular degeneration (wet AMD) in the European Union (EU). The Positive Implications: This positive opinion from the CHMP underscores the potential approval of ONS-5010/LYTENAVA™, which stands to revolutionize the landscape of wet AMD treatment in the EU. If granted final authorization by the European Commission (EC), ONS-5010/LYTENAVA™ would mark the first on-label, ophthalmic bevacizumab approved for the treatment of wet AMD in the region. Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, expressed pride in this achievement, emphasizing its significance in advancing wet AMD treatment options. He highlighted the company's commitment to delivering innovative solutions to address critical unmet needs in ophthalmic care. Clinical Basis and Market Potential: The CHMP's positive opinion was founded upon robust clinical data derived from Outlook Therapeutics' comprehensive wet AMD clinical program for ONS-5010. This program encompassed three pivotal registration trials—NORSE ONE, NORSE TWO, and NORSE THREE—alongside supportive studies and bibliographic literature. The efficacy and safety demonstrated across these trials signal promising prospects for ONS-5010/LYTENAVA™ as a viable therapeutic option for wet AMD patients. Furthermore, ONS-5010/LYTENAVA™ offers a compelling alternative to current treatment modalities. Unlike existing practices involving the repackaging of intravenous bevacizumab by compounding pharmacies, ONS-5010/LYTENAVA™ eliminates concerns regarding contamination, inconsistent potency, and availability. By providing a standardized, approved formulation, ONS-5010/LYTENAVA™ ensures greater reliability and safety for clinicians and patients alike. Looking Ahead: The anticipated authorization of ONS-5010/LYTENAVA™ holds immense promise not only for Outlook Therapeutics but also for the broader medical community and patients grappling with wet AMD in the EU. The potential introduction of this innovative treatment stands to enhance therapeutic outcomes, mitigate risks associated with current practices, and ultimately improve the quality of life for individuals affected by this debilitating condition. As the EC deliberates on the CHMP's recommendation, stakeholders across the healthcare spectrum await the imminent decision with bated breath. Should ONS-5010/LYTENAVA™ receive final approval, it would signify a monumental leap forward in the fight against wet AMD, reaffirming Outlook Therapeutics' commitment to innovation and patient-centric care.
NASDAQ:OTLKLong
by DEXWireNews
$OTLK is gonna fall todayPupm&Dump trading strategy idea. $OTLK is rising too much today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $2,89; stop-loss — $3,20; take-profit — $2,27. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:OTLKShort
by KozakHlib
7
$OTLK good buy for long term investment$OTLK seems to be breaking out upside on the bullish news - reported statistically significant achievement on Phase 3 trial for both Primary and Secondary endpoints! The chart also shows the double bottom pattern completed with parallel channel formed above it, which is now being broken out upward. Irregardless where it goes in short term, the company has potential to have 12 years of marketing exclusivity if their BLA get's approved. Good buy range: $2.2 - $4 Potential downside - $1.6-$1.8 Price isn't too bad with current estimated global market of $13.1B
NASDAQ:OTLKLong
by aniHotmail
OTLK Swing-trade (and potential long-term growth) ideaOTLK (Outlook Therapeutics, Inc.) is expected to commercialize the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan, Greater China and other markets. The stock recently spiked up in anticipation of the most recent earnings report, and experienced a brief pullback as "earnings/news" focused traders took profits. The base appears to have now consolidated, with the down trend now reversing into a positive uptrend with great potential as a swing-trade and long-term investment. (Just my opinion)
NASDAQ:OTLKLong
by khollspati
2
$OTLK Secures Funding to Support ONS-5010 / LYTENAVA™Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $35.0 Million announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 35,000,000 shares of common stock of Outlook Therapeutics, at a price to the public of $1.00 per share, less underwriting discounts and commissions. finance.yahoo.com Outlook Therapeutics Announces Closing of $35.0 Million Bought Deal finance.yahoo.com Outlook Therapeutics’ Recent Financing Secures Funding to Support ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Through Planned BLA Submission The combined net proceeds from these stock offerings are expected to provide sufficient capital to fund operations through the expected filing of the Biologics License Application (BLA) for ONS-5010 for wet age-related macular degeneration (wet AMD), which is planned for the end of calendar 2021 . “Not only have we secured enough capital to significantly extend our cash runway through important upcoming milestones in 2021, but we have provided ourselves with more time to unlock the greatest value and potential for ONS-5010, the company, and our stockholders. We believe we are now in an improved position that will allow us to both maximize the value of this asset and to provide an FDA-approved ophthalmic formulation of bevacizumab to patients .” Extensive market research indicates that ONS-5010, if approved, will be a significant therapy in the retinal anti-VEGF market, currently estimated to be in excess of $13 billion worldwide. Clinical Progress of ONS-5010 On Track - Therapeutics expects to report pivotal safety and efficacy data in the third calendar quarter of 2021. finance.yahoo.com
NASDAQ:OTLK
by AlenCiken
OTLK Breakout Stock Alert Update | 174% Profit GainBREAKOUT STOCK ALERT UPDATE $OTLK - Outlook Therapeutics, Inc. - Common Stock (CV EM) Initial Alert Price: $1.32 Price High: $3.62 % Gains/Losses: 174.24% (+154.3% More Than Expected) Potential Stop Loss: $3.439 OTLK opened in today's trading session hit $3.62 in today's session without showing any company news to justify the move. This trade unfolded over the course of the trading sessions from Feb. 3rd, 2021. The move provided a +174% Profit Gain on our original trade alert from Jan. 22nd, 2021 and we are currently seeing a pullback to the $3.05 Price Levels. With a trade like this, we always and will always suggest the Spilt-And-Run Method of managing initial investment risks by selling 50% of current positions here and allowing the profits to continue making money for you moving forward. #Breakout #Stocks #Trading #Investing #Alerts #StockMarket #Daily #News #Today
NASDAQ:OTLKLong
by MyMIWallet
OTLK Breakout Stock Alert UpdateBREAKOUT STOCK ALERT UPDATE $OTLK - Outlook Therapeutics, Inc. - Common Stock (CV EM) Initial Alert Price: $1.32 Price High: $1.65 % Gains/Losses: 25% (+5.3% More Than Expected) Potential Stop Loss: $1.5675 OTLK bounced back to the $1.65 Price Level into Today's Trading Session before meeting resistance and consolidating back the $1.42 to find additional support at those levels. The stock is actually sitting right at our Price Target around the $1.58 providing our 30% Target Gains from the initial trade alert, but after finding support around the $1.40 Levels of Resistance, we could see the stock continuing to trade within the $1.40 - $1.78 over the new few trading session to again retest those $1.73 Levels of Resistance. This comes after the Director GM Ventures & Investments reported purchasing 8.36M Shares at $1.00/Share in Form 4 Filings on Tuesday. The next price ranges beyond those $1.73 Price Levels would be between the $1.73 - $2.89 Price Ranges #Breakout #Stocks #Trading #Investing #Alerts #StockMarket #Daily #News #Today
NASDAQ:OTLKLong
by MyMIWallet
OTLK Breakout Stock Alert UpdateBREAKOUT STOCK ALERT UPDATE $OTLK - Outlook Therapeutics, Inc. - Common Stock (CV EM) Initial Alert Price: $1.32 Price High: $1.03 % Gains/Losses: -21.97% (-41.7% Less Than Expected) Potential Stop Loss: $0.9785 OTLK recently announced a $35 Million Common Stock Offering which cause the stock to drop 20% during today's pre-market session. We would stand to suggest one of two options here. Option 1: Hold until the stock offering closes, allowing the stock to rebound back to higher price levels. It is key to keep in mind that it is not a bad when a company provides a common stock offering to access more liquidity as needed (which is the whole purpose of a company being publicly traded to begin with) in order to ramp up operations. Option 2: Cut your loses and move on the next trade. With that being said, we are currently not closing this trade just yet in order to allow for the stock offering to come to a close. The stock actually jumped to $1.40 for a 6% gain from our original trade alert, which was -13% less than our target gains on the trade. So we're going to let this play out as it's only $0.38 below our initial entry price on the trade, but it may require a longer hold in order to profit from the gain. The stock is currently showing a reversal on the 1-Hr. as it is oversold on that timeframe. Keep an eye on this moving forward in order to make sure we don't dip below that $0.92 Price Levels moving forward. We have alerts set to push out a sell alert if deemed necessarily to protect further loses. #Breakout #Stocks #Trading #Investing #Alerts #StockMarket #Daily #News #Today
NASDAQ:OTLK
by MyMIWallet